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Background: The multiple tyrosine kinase inhibitors SU6668 have a promising therapeutic effect on the
progression of hematological malignancies and some solid tumors. Here, we determined its effect on triple
negative breast cancer (TNBC) cells and explored the potential molecular mechanism.
Methods: In this study, MDA-MB-231 cells were treated with SU6668 (15 μM, 30 μM) for 72 h and the change of
proliferation was examined by MTT and tablet cloning. DNA ploidy was detected by flow cytometric analysis with
PI staining. Double-label immunofluorescence method was used to detect the expression and distribution of MTDH
proteins. VEGFR2, HIF-1α, MTDH, E-cadhrein, and SMA expressions were detected by Western bolt assay.
Results: This study showed that SU6668 inhibited the proliferation and induced polyploidization of MDA-MB-231
cells in a dose dependent form. SU6668 exposure increased the distribution of MTDH in cytoplasm and decreased
its distribution in nuclei. After the treatment of SU6668, VEGFR2, HIF-1α, MTDH and SMA proteins were down-
regulated, while E-cadhrein was up-regulated in MDA-MB-231 cells.
Conclusions: In conclusion, SU6668 exposure maybe induces polyploidization, inhibit EMT and influence the
expression of MTDH, which suppresses the proliferation in TNBC cells. MTDH is a key signal protein in downstream
of VEGF/HIF-1αpathway in MDA-MB-231 cells, which may be used as the potential target in the treatment of TNBC.
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TNBC is defined as estrogen receptor, progesterone re-
ceptor and human epidermal growth factor receptor
type 2 (HER2) negativity. Its incidence accounts for 15%
of breast cancers. Although the proportion is not high, it
is easy to recurrence and metastasis with a poor progno-
sis of malignant characteristics [1,2]. Due to the lack of
endocrine and HER2-target therapeutics, the treatment
for TNBC is still the hot spot and difficulty of present
clinical research. So far, there is no special guideline for
TNBC treatment. Because of its chemo sensitivity, most
of clinicians choose anthracycline-based and yew-based
chemotherapy regimens. Some studies focus on microtu-
bules stabilizer (e.g. Docetaxel) and receptor tyrosine* Correspondence: doctor_xxd@163.com
†Equal contributors
1Oncology Department, Cancer Treatment Center, General Hospital of
Shenyang Military Region, Shenyang, P. R. China
Full list of author information is available at the end of the article
© 2013 Wang et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orkinase inhibitor (e.g. Erlotinib), which can suppress
tumor proliferation by blocking mitosis and receptor
tyrosine kinase [3].
MTDH gene, also called astrocyte elevated gene 1
(AEG-1) gene, was originally from human embryonic as-
trocytes cloning. It is significantly over-expressed in
many tumor tissues and closely related to proliferation,
angiogenesis, invasion, metastasis and treatment resist-
ance of breast cancer; it has the potential to be an effect-
ive therapy target gene [4,5].
Polyploidy plays an important role in development of
cells, and is also related to human diseases, especially
cancer [6]. Although polyploidy occur frequently in most
multicellular organisms and human cancers, but the
knowledge of polyploidy state function is still quite lim-
ited. A polyploid cell can be either blocked in the cell
cycle, or regain potentially cancerous proliferation. Re-
cent studies suggested that some drug could inducetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Absorbance value and cell growth inhibition rate
of MDA-MB-231 cells treated with different
concentrations SU6668
Concentration of SU(μM) n OD value Growth inhibition rate (%)
0 5 1.74 ± 0.26 -
6.25 5 1.68 ± 0.17 4.55 ± 0.98
12.5 5 1.63 ± 0.08 6.32 ± 1.01
18.75 5 1.54 ± 0.13 11.49 ± 0.53
25 5 1.46 ± 0.06 16.09 ± 1.17
31.25 5 1.27 ± 0.11 27.01 ± 0.82
37.5 5 0.97 ± 0.08 44.25 ± 1.36
43.75 5 0.82 ± 0.09 52.87 ± 2.01
50 5 0.47 ± 0.12 72.99 ± 1.94
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tumor activity by blocking mitosis, inhibiting cell prolifera-
tion ability and promote the cell-aging process [7].
Excessive activation of tyrosine kinase is closely related
to tumorigenesis, development, prognosis and outcomeFigure 1 Concentration-suppression curve of MDA-MB-231 cells treat
supplemented with SU6668 (0-60μM) for 72h. The media were then replac[8]. More and more tyrosine kinase inhibitors has been
developed to be new antitumor drugs. As one of them,
SU6668 was discovered in 2000 [9]. Studies showed that
it inhibited receptor tyrosine phosphorylation and mi-
tosis to suppress tumor cell proliferation, and had a
therapeutic effect on a variety of solid tumors and
hematological malignancies [10-12]. However, the effect
of SU6668 on TNBC has not yet been reported.
Results
SU6668 suppressed proliferation in MDA-MB-231 cells
Treated with different concentrations SU6668, MDA-
MB-231 cells proliferation was significantly inhibited in
a dose dependence form. In the concentration of 15 μM
and 30 μM, the cell inhibitory rate were 10% and 20%
respectively, so 15 μM and 30 μM were chosen for our
later experiments (Table 1, Figure 1).
SU6668 inhibited clone formation in MDA-MB-231 cells
After SU6668 treatment, the single colony of 15 μM and
30 μM group was obviously smaller than controled with SU6668. MDA-MB-231 cells were cultured in media
ed with MTT working reagent for 4 h, and DMSO was added finally.
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(59 ±7.1, 26 ± 3.5) than the control group (107 ± 15.4) in
a dose dependence form (Figure 2).
SU6668 influenced the morphology in MDA-MB-231 cells
Under optical microscopy, we observed that cells’ con-
tour was clear and connected closely in 15 μM group,
while cells’ morphology had no significant change in the
control group. In 30 μM group, the cells’ contour was
fuzzy, transparency was reduced, intercellular structure
was loose. Meanwhile, the number of nuclei was in-
creased and a small amount of apoptosis morphological
changes was found at high magnification (Figure 3).
SU6668 induced DNA polyploidization in MDA-MB-231 cells
After PI staining, SU6668 treated DNA content was
tested by flow cytometry. The results showed that tetra-
ploid increased after SU6668 processing in a dose
dependence form. With the increasing percentage of
G2/M phase (tetraploid) cells, the percentage of G1
phase (diploid) cells was reduced (Figure 4).Figure 2 Clone formation of MDA-MB-231 cells treated with SU6668.
(15μM, 30μM) for 72h. After three weeks, cells were fixed with methanol fo
with control group, P<0.05.SU6668 influenced MTDH distribution in MDA-MB-231 cells
Under laser confocal microscope, blue fluorescence rep-
resented the nuclei positive staining and green fluores-
cent represented MTDH protein positive staining. In the
control group, green fluorescence was mainly distributed
in the cytoplasm surrounding nucleus. In the treatment
groups, the intensity of green fluorescence was de-
creased, less expressed in cytoplasm and relatively more
expressed in nucleus. All of the findings were in a dose
dependence form (Figure 5).SU6668 down-regulated VEGFR2, HIF-1α, MTDH, SMA and
up-regulated E-cadherin in MDA-MB-231 cells
After dealing with SU6668, the expression of proteins
related to angiogenesis, invasion and metastasis were
detected by Western blotting. MDA-MB-231 cells were
treated with 15 μM and 30 μM for 72 h, the expression
of VEGFR2, HIF - 1α, MTDH, SMA protein were sig-
nificantly decreased, while the expression of E-cadherin
protein increased obviously (Figure 6).MDA-MB-231 cells were cultured in media supplemented with SU6668
r 15 min, then stained with Giemsa for 20 min.＊means compared
Figure 3 Morphologic change of MDA-MB-231 cells treated with SU6668. MDA-MB-231 cells were cultured in media supplemented with
SU6668(15μM, 30μM) for 72h, and observed under optical microscopy with 10, 20 and 40-fold magnification.
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TNBC is common in premenopausal young women, cell
proliferation ratio is high, prognosis is poorer, the 5-year
survival rate is less than 15% [13]. More and more small
molecular compounds have been used to blocking the
cell cycle, by inhibiting the mitosis process, promoting
polyploidization and cell apoptosis, thus play a role of
anti-tumor. Among them, the study from Gully and his
colleague suggests a precursor of AZD1152 has potential
therapeutic value for different molecular biology types of
breast cancer, this finding provides a new choice that for
TNBC treatment, which lacks of drug targets [7].
Scholars have devoted to tyrosine kinase inhibitor and
have made great breakthroughs. Gleevec and Iressa have
been approved by the United States FDA for separately
used in treatment of chronic myelogenous leukemia and
advanced non-small cell lung cancer, and acquire remark-
able effect. SU6668, a kind of tyrosine kinase inhibitors, can
act on VEGFR-2, PDGFR-beta and FGFR1, competing with
ATP binding site so as to inhibit the activity of tyrosine kin-
ase [9]. Its treatment decreased tumor cell proliferation, in-
duced tumor endothelial cell apoptosis. Intraperitoneal
injection or oral SU6668 could inhibit growth of transplant-
ation tumor like glioma, melanoma, lung cancer, colon can-
cer, ovarian cancer in nude mouse [9].Hu and his colleague found that MTDH gene was
over-expressed in more than 40% of breast cancer pa-
tients, which not only promoted the metastasis of tumor
cells, but also enhanced the resistance to chemotherapy
drugs and affected the clinical therapeutic effect [14].
Recently, Li reported that MTDH was not expressed in
normal mammary epithelial cells, but expressed with dif-
ferent extent in breast cancer cell lines [5]. The expres-
sion of MTDH gene positively correlated with the
clinical stage of breast cancer, prompting that MTDH
gene expression may be considered as an independent
prognostic indicator for breast cancer [5]. Howerver, the
function and significance of MTDH gene in TNBC cells
have been rarely reported.
Epithelial-mesenchymal transformation (EMT) play an
irreplaceable role in tumor proliferation and invasion
process, and are also closely related with tumor distant
metastasis and drug resistance [15]. Studies suggested
that up-regulated MTDH expression in MCF-7 cells,
protein fiber connection expression was increased, and
E-cadherin expression was reduced, that could promote
the EMT process to enhance cell invasion and migration
ability [5].
E-cadherin belongs to the family of cell adhesion
molecule protein, and is widely expressed in various
Figure 4 DNA ploidy of MDA-MB-231 cells treated with SU6668. 001: con group, 002: 15μM group, 003: 30μM group. MDA-MB-231 cells
were cultured in media supplemented with SU6668(15μM, 30μM) for 72h, then incubated in PI solution for 30min, detected cell fluorescence
intensity, which excitative wavelength was 488nm, and the emissive wavelength was 630nm. After SU6668 treatment, the tetraploid increased in
a dose- dependent manner. With the increasing percentage of G2/M phase (tetraploid) cells, the percentage of G1 phase (diploid) cells was
reduced.
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was a close relationship between tumor metastasis and
EMT, absent or suppressed expression of E-cadherin
may be a key link in starting invasion and metastasis
process, down-regulating E-cadherin expression can in-
validate the adhesion function between cells, and lead to
separation of adjacent cells [17]. The development of
breast cancer may be associated with abnormal function
of E-cadherin, so it is suggested to be an important indi-
cator to detect the development of breast cancer [18].
α-SMA participates in the form of microfilament
structure in eukaryotic cell, and acts as a cytoskeleton
protein [19]. Higher expression of α-SMA in the tissues
indicates the existence of EMT [20,21]. α-SMA expres-
sion has a certain relationship with tumor angiogenesis
in a majority of tumors, which mainly affects the gener-
ation of tumor blood vessels directly or indirectly by
regulating the activity of cell proliferation and the ex-
pression of VEGF [22].
The combination of VEGF and its receptors has a
strong effect in angiogenesis, increasing vascular perme-
ability, providing matrix to establish a new capillarynetwork, and promoting the growth of tumor cells.
Studies found that the expression of MTDH in TNBC
had a positive relationship with the level of VEGF1 and
microvascular density [23].
In the development of solid tumor, angiogenesis is in-
sufficient to meet the rapid growth of the tumor blood
supply, thus leads to local hypoxia, and up-regulates the
expression of HIF-1α. The downstream genes are in-
volved in enhancing tumor invasion and metastasis abil-
ity, so as to improve its adaptability to relatively low
oxygen environment. The increased expression of HIF-
1α is very common in a variety of human tumors and
some precancerous lesions, indicating that its expression
may be an early event in tumor progression [24].
Research showed that SU6668 played an important
role in inhibiting proliferation and angiogenesis of tumor
cells by down-regulating the expression of VEGFR2 and
HIF-1α, [10,11]. Hypoxia induced activation of MTDH
through PI3K/AKT pathway. Stabilizing the feedback of
HIF-1α and MTDH, and activating PI3K would form a
positive feedback loop to enhance tumor cells’ survive
and the progression [25]. At the same time, it was
Figure 5 MTDH distribution of MDA-MB-231 cells treated with SU6668. A: con group; B: 15μM group; C: 30μM group (A1,B1,C1 showed
nucleus tagged with blue fluorescent. A2, B2, C2 showed MTDH proteins tagged with green fluorescent. A3, B3, C3 were fused images). MDA-MB-
231 cells were cultured in media supplemented with SU6668 (15μM, 30μM) for 72h.
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level of transcription through NF-κB pathway [26].
Conclusions
Our study investigated for the first time the effect of
SU6668 on TNBC cells, in order to provide research
basis for developing new strategy in TNBC treatment.
We found that the phenomenon of polyploidization
appeared among cells, prompted that SU6668 processinginduced mitotic arrest. SU6668 could inhibit angiogenesis
and EMT through inducing DNA polyploidization, so as
to inhibit the growth and proliferation of TNBC cells. Our
results also showed that SU6668 down-regulated the ex-
pression of MTDH and other metastasis-related proteins,
up-regulated the expression of metastasis suppressor. The
findings indicated that MTDH may play a key role in sig-
naling pathways of angiogenesis, invasion and metastasis
in TNBC. However, the development of TNBC involved
Figure 6 Related proteins expression of MDA-MB-231 cells treated with SU6668. Western blot showed that exposure to various
concentrations of SU6668 (15μM, 30μM) for 72h resulted in related proteins expression change of MDA-MB-231 cells (A). The protein expression
of VEGFR2 (B), HIF-1α (C), MTDH (D), SMA (F) were significantly decreased after SU6668 treatment, while the protein expression of E-cadherin (E)
was increased obviously. The results were compared between each two groups. * P < 0.05, indicated significant differences from the control
group, # P < 0.05, indicated significant differences from the 15μM group.
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on the potential target genes should be proceeded to ob-
tain promising regimens for TNBC.Methods
Cell cultures
The human TNBC cell line (MDA-MB-231) were cultured
in high-glucose Dulbecco’s Modified Eagle Medium
(DMEM; Gibco Corporation, USA), supplemented with10% fetal calf serum (Hyclone, USA) at a temperature of
37°C, 5% CO2, 95% oxygen, and 95% humidity.MTT
1 × 103 MDA-MB-231 cells were planted into 96-well
plates. After 24 h, different concentration of SU6668 was
added to culture medium, and continued to cultivate for
72 h. MTT (20 μl/well) was added and developed for
4 h, DMSO (150 μl/well) was added finally. The
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reader. The concentration-suppression curve was drawn,
and the inhibition rate was calculated. Inhibition rate =
(1 - experimental group A/control group A) × 100%.
Tablet cloning
200 MDA-MB-231 cells were planted into 9 cm petri
dish. After 72 h SU6668 processing, PBS was used to
wash cells for 3 times and fresh medium was added.
After three weeks, 5 ml methanol was added to fix cells
for 15 min. Giemsa was used to stain cells for 20 min,
washed off with slow water, and was dried by air. The
clone formation rate was calculated under microscope,
clone formation rate (%) = (clone number/plated cell
number) × 100%.
Flow cytometric
Processed the logarithmic phase of MDA-MB-231 cells
with SU6668 for 72 h, collected cells and fixed punch
with cold methanol, washed with PBS for three times,
then incubated in PI solution including RNaseA at room
temperature away from light, after 30 min, detected cell
fluorescence intensity by flow cytometry instrument,
which excitative wavelength was 488 nm, and the emis-
sive wavelength was 630 nm.
Immunofluorescence
2.5 × 105 MDA-MB-231 cells were planted into glass cul-
ture chambers. After 72 h SU6668 processing, washed
with PBS for twice. 3% paraformaldehyde fixed at 4°C,
30 min. Washed with PBS for three times. Then, sec-
tions were incubated with first primary antibody MTDH
(1:40) for 8 h at 4°C and Cy3-labeled goat anti-rabbit
IgG (1:150) for 1 h at 25°C by turns. After being washed
in PBS 3times, the nuclear antibody To-Pro3(1:1000)
were added to the sections for 5 min at 25°C, then
washed in PBS three times. The protein expression was
observed by fluorescence microscope after being
counterstained with DAPI and mounted with water-
solubility mounting agents.
Western bolt
Processed the logarithmic phase of MDA-MB-231 cells
with SU6668 for 72 h, collected and cracked cells,
extracted proteins, determined protein content with
BCA method. Took 25 μg protein, separated with 12%
sds-page method, transferred to the PVDF membrane,
closed with 5% skim milk for 3 h at 25°C, added first pri-
mary antibody(1:100) for 8 h at 4°C, washed with TBST
for three times, and second antibody (HRP-anti-rabbit
1:2,000, HRP-anti-Mouse 1:6,000, and HRP-anti-Biotin
1:6,000) for 2 h at 25°C, washed with TBST for three
times. Took TBP as internal protein.Statistical analysis
Experiments were repeated for three times. Image J soft-
ware was adopted to improve the half quantitative analysis
of protein electrophoresis gray levels. The measurement
data was expressed as mean ± standard deviation(SD).
Statistical analysis, including ANOVA test, and q test, were
carried out using the software package SPSS 16.0. The sig-
nificance level was set at 5% for each analysis.
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